These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6140172)

  • 1. Cardiovascular pharmacology of ASL-8052, an ultra-short acting beta blocker.
    Murthy VS; Hwang TF; Zagar ME; Vollmer RR; Schmidt DH
    Eur J Pharmacol; 1983 Oct; 94(1-2):43-51. PubMed ID: 6140172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
    Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blocking and hemodynamic effects of ASL-8052.
    Gorczynski RJ; Murthy VS; Hwang TF
    J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular pharmacology of ACC-9089--a novel, ultra-short-acting, beta-adrenergic receptor antagonist.
    Gorczynski RJ; Vuong A
    J Cardiovasc Pharmacol; 1984; 6(4):555-64. PubMed ID: 6206307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.
    Shaffer JE; Quon CY; Gorczynski RJ
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):187-92. PubMed ID: 2452313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.
    Gorczynski RJ; Reynolds RD
    J Pharmacol Exp Ther; 1985 Mar; 232(3):629-35. PubMed ID: 2857783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.
    Sponer G; Bartsch W; Strein K; Müller-Beckmann B; Böhm E
    J Cardiovasc Pharmacol; 1987 Mar; 9(3):317-27. PubMed ID: 2437399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic studies on prizidilol and nipradilol (K-351), antihypertensive drugs with combined vasodilator and beta-adrenoceptor blocking actions, in rabbits.
    Kawashima K; Watanabe TX; Sokabe H
    Jpn J Pharmacol; 1984 Dec; 36(4):519-26. PubMed ID: 6151998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of ASL-8052, a novel beta-adrenergic receptor antagonist with an ultrashort duration of action.
    Gorczynski RJ; Shaffer JE; Lee RJ
    J Cardiovasc Pharmacol; 1983; 5(4):668-77. PubMed ID: 6193366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insurmountable beta receptor blockade by ICI 147,798 in rabbits.
    Murthy VS; Hwang TF; Wurm R; Zagar ME; Keith RA; Kau ST; Salama AI; Giles RE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):249-55. PubMed ID: 2563289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats.
    Shibasaki K; Uchida W; Takizawa K; Masuda N; Okazaki T; Inagaki O; Asano M; Takenaka T
    Biol Pharm Bull; 1997 Mar; 20(3):230-6. PubMed ID: 9084878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs.
    Grohs JG; Fischer G; Raberger G
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):175-81. PubMed ID: 1689410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
    Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
    J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker.
    Turlapaty P; Burge J; Hulse J; Achari R; Bell V; Mosberg H; Laddu A
    Clin Pharmacol Ther; 1986 May; 39(5):543-9. PubMed ID: 3698462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
    Reilly CS; Wood M; Koshakji RP; Wood AJ
    Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity.
    Sheu MM; Wu BN; Ho WC; Hong SJ; Chen SJ; Lin YT; Chen IJ
    Pharmacology; 1997 Apr; 54(4):211-24. PubMed ID: 9211567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the hypotensive effect of a new beta-adrenergic blocking drug, arotinolol (S-596) in anesthetized rabbits.
    Nakahara H; Nakazawa M; Tsukada T; Imai S
    Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):253-63. PubMed ID: 2415080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of YM-16151-1 and its optical isomers: a novel calcium entry blocking and beta 1-adrenoceptor blocking agent.
    Uchida W; Shibasaki K; Asano M; Takenaka T
    Arch Int Pharmacodyn Ther; 1993; 321():30-40. PubMed ID: 8100704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some cardiovascular effects of timolol a new beta-adrenergic blocking agent.
    Scriabine A; Torchiana ML; Stavorski JM; Ludden CT; Minsker DH; Stone CA
    Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):76-93. PubMed ID: 4148410
    [No Abstract]   [Full Text] [Related]  

  • 20. Beta adrenergic stimulation and blockade in cirrhosis: effects on azygos vein blood flow and portal hemodynamics.
    Weinshel EH; Altszuler HM; Raicht RF; Sedlis SP
    Am J Med Sci; 1994 Jun; 307(6):396-400. PubMed ID: 7911005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.